BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/1/2021 12:36:04 PM | Browse: 879 | Download: 2656
 |
Received |
|
2020-10-09 09:17 |
|
Peer-Review Started |
|
2020-10-09 09:17 |
|
First Decision by Editorial Office Director |
|
2020-11-03 00:39 |
|
Return for Revision |
|
2020-11-03 00:39 |
|
Revised |
|
2020-11-09 07:59 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-16 11:29 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-21 05:47 |
|
Articles in Press |
|
2020-11-21 05:47 |
|
Edit the Manuscript by Language Editor |
|
2020-11-26 23:01 |
|
Typeset the Manuscript |
|
2020-12-28 15:12 |
|
Publish the Manuscript Online |
|
2021-01-01 12:36 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ci Tian, Nan Li, Yi Bai, Han Xiao, Shu Li, Qing-Gang Ge, Ning Shen and Qing-Bian Ma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Bian Ma, MD, Associate Professor, Chairman, Chief Physician, Department of Emergency Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. maqingbian@bjmu.edu.cn |
| Key Words |
COVID-19; Hypertension; Angiotensin converting enzymes inhibitors; Angiotensin receptor blockers; Angiotensin-converting enzyme-2; Prognosis |
| Core Tip |
Recent research revealed that the ingestion of angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no significant harm on coronavirus disease 2019 (COVID-19) patients complicated with hypertension. However, the impact of discontinue using ACEIs/ARBs in those patients was still unclearly. In the present study, we retrospectively collected the clinical data of patients with both COVID-19 and hypertension, and to explore whether any difference in disease outcomes occurred between patients who discontinued using ACEIs/ARBs and those who continued using other anti-hypertensive drugs. |
| Publish Date |
2021-01-01 12:36 |
| Citation |
Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i1/47.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i1.47 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
